A world‐wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. (28th June 2016)

• Record Type: Journal Article
• Authors: Turecek, P. L.; Romeder‐Finger, S.; Apostol, C.; Bauer, A.; Crocker‐Buqué, A.; Burger, D. A.; Schall, R.; Gritsch, H.
• Is Part Of: Haemophilia. Volume 22:Number 6(2016:Nov.)
• Page Start: 957
• Page End: 965
• Publication Date: 2016-06-28
• Subjects: acquired haemophilia -- chromogenic assay -- FVIII assay -- haemophilia -- one‐stage clotting assay -- PEG FVIII -- porcine FVIII; Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.13001
• Languages: English
• ISSNs: 1351-8216

Abstract

Abstract : Introduction: Discrepancies have been previously reported for one‐stage clotting and chromogenic assays for FVIII activity analysis. Inter‐laboratory variations in instruments, method of clot detection, assay set‐up, reference standard calibration, reagent source and reagent composition all contribute to assay variability. Aim: To characterise multilaboratory assay variability in measuring ADYNOVATE, OBIZUR and ADVATE FVIII activity in human plasma and survey multinational FVIII activity assay preferences. Methods: As samples from patients treated with either of the FVIII products are not available in the quantities required for a systematic collaborative study, haemophilia A plasma was spiked in vitro with either ADYNOVATE (PEGylated rFVIII), OBIZUR [Porcine Sequence Antihaemophilic Factor (Recombinant)] or ADVATE at high (0.80 IU or U mL −1 ), medium (0.20 IU or U mL −1 ) and low (0.05 IU or U mL −1 ) FVIII concentrations, based on labelled potencies. Clinical laboratories used their routine FVIII activity assay to determine FVIII activity of each product. Thirty‐five data sets using one‐stage clotting assay and 11 sets using chromogenic assay were obtained. Results: A vast majority of laboratories (98%) prefer and rely on the one‐stage clotting assay. Mean recoveries across all concentrations were 113%, 120% and 127% for ADYNOVATE, OBIZUR and ADVATE respectively. Assay variation was comparable between ADVATE, ADYNOVATE and OBIZUR with inter‐laboratory percent coefficients of variation (%CV) ranging from 11 to 22%. Mean chromogenic assay results were 116%, 51% and 113% for ADYNOVATE, OBIZUR and ADVATE respectively. Inter‐laboratory CV's were similar for ADYNOVATE, OBIZUR and ADVATE. Conclusions: One‐stage clotting assays can and will be used with sufficient accuracy and precision for the measurement of ADYNOVATE, OBIZUR and ADVATE in plasma samples from subjects with haemophilia A. Chromogenic assay underestimates OBIZUR potency, particularly at lower concentrations.